b 31 has been researched along with Breast Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gavin, PG; Kim, SR; Pogue-Geile, K | 1 |
| Boggiani, D; Musolino, A; Viansone, AA | 1 |
| Badve, S; Bandos, H; Costantino, JP; Demaria, S; Eynden, GGGMVD; Fehrenbacher, L; Floris, G; Gavin, PG; Geyer, CE; Kim, RS; Kos, Z; Lucas, PC; Mamounas, EP; Paik, S; Pogue-Geile, KL; Rastogi, P; Salgado, R; Song, N; Swain, SM; Wickerham, DL; Wolmark, N | 1 |
| Dolcetti, R | 1 |
4 other study(ies) available for b 31 and Breast Cancer
| Article | Year |
|---|---|
Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors-Reply.
Topics: Breast Neoplasms; Humans; Immunoglobulin G; Prognosis; Pyrimidines; Receptor, ErbB-2; Receptors, IgG; Trastuzumab | 2018 |
Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors.
Topics: Breast Neoplasms; Humans; Immunoglobulin G; Prognosis; Pyrimidines; Receptor, ErbB-2; Receptors, IgG; Trastuzumab | 2018 |
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Female; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Pyrimidines; Receptor, ErbB-2; Receptors, IgG; Stromal Cells; Trastuzumab | 2019 |
Predictive Value of FcR Polymorphisms: A Further Step on the Long and Winding Road to Application.
Topics: Breast Neoplasms; Humans; Pyrimidines; Receptor, ErbB-2; Receptors, IgG; Trastuzumab | 2017 |